REG - BioPharma Credit PLC - NEW INVESTMENT OF US$125 MILLION

Biopharma CreditAnnouncement

17/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260317:nRSQ8710Wa&default-theme=true

RNS Number : 8710W  BioPharma Credit PLC  17 March 2026

17 March 2026

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

NEW INVESTMENT OF US$125 MILLION

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment
trust, is pleased to announce that it, through its fully owned subsidiary,
together with BioPharma Credit Investments V (Master) LP ("BioPharma-V"), have
entered into a new senior secured loan agreement (the "Loan Agreement") with
Zenas BioPharma, Inc. ("Zenas").  The Company will invest up to US$125
million and BioPharma-V will invest up to an additional US$125 million in
parallel, with the Company acting as collateral agent.

 

Under the Loan Agreement, the Company will invest up to US$125 million across
five tranches, subject to customary conditions precedent:

·    Tranche A of US$37.5 million will be funded ten business days
following the execution of the Loan Agreement;

·    Tranche B of up to US$37.5 million is available to be drawn by 1
November 2027, of which US$25 million is required to be drawn upon certain
regulatory approvals;

·    Tranche C of up to US$12.5 million (less any amounts elected to be
and actually drawn under Tranche B in excess of US$25 million) is available to
be drawn by 28 April 2028, subject to certain regulatory approvals;

·    Tranche D of US$25 million is available to be drawn by 30 October
2028, subject to achievement of certain milestones in respect of regulatory
approvals and certain net sales levels; and

·    Tranche E of US$25 million is available to be drawn by 30 April 2029,
subject to achievement of certain milestones in respect of regulatory
approvals and certain net sales levels.

The loan will mature in March 2031 and will bear interest at 3-month SOFR
plus 5.75 per cent. per annum subject to a 3.25 per cent. SOFR floor. A
one-time additional consideration of 2.00 per cent. of Tranche A and US$50
million of Tranche B, and 1.00 per cent. of any amounts in excess of US$50
million of the funding amount for Tranche B and each of Tranche C, D and E, is
payable by Zenas upon the funding of each respective tranche.

Zenas is a clinical-stage global biopharmaceutical company committed to
becoming a leader in the development and commercialization of transformative
therapies for patients with autoimmune diseases with a  current market
capitalization of ~US$1.25 billion (Ticker: ZBIO - NASDAQ).  Zenas is
advancing two late-stage, potential franchise molecules, obexelimab and
orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional
monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly
present across the B cell lineage, to inhibit the activity of cells that are
implicated in many autoimmune diseases without depleting them. The
registrational obexelimab Phase 3 INDIGO trial for immunoglobulin G4-related
disease (IgG4-RD) met its primary endpoint and all four key secondary
endpoints with high statistical significance, and Zenas is on track to submit
a BLA for IgG4-RD to the FDA in 2Q26.

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKABPBBKBOND



            Copyright 2019 Regulatory News Service, all rights reserved